Compare BFRG & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRG | PFSA |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 11.1M |
| IPO Year | 2023 | N/A |
| Metric | BFRG | PFSA |
|---|---|---|
| Price | $1.12 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 68.3K | ★ 10.1M |
| Earning Date | 11-14-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,670.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 122.22 |
| 52 Week Low | $0.80 | $0.10 |
| 52 Week High | $4.84 | $12.76 |
| Indicator | BFRG | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.78 | N/A |
| Support Level | $0.98 | N/A |
| Resistance Level | $1.21 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 63.71 | 0.00 |
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.